Skip to content

Wound Additives in Primary Total Joint Athroplasty

The Effects of Platelet-Rich Plasma and Activated Collagen on Wound Healing in Primary Total Joint Arthroplasty

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03158623
Enrollment
90
Registered
2017-05-18
Start date
2016-04-01
Completion date
2016-12-20
Last updated
2017-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthroplasty, Replacement

Keywords

total joint arthroplasty, platelet-rich plasma, activated collagen

Brief summary

3 cohorts of total joint patient of 30 members each were randomized to receive PRP or Activated Collegen or no additive were studied for status of the wound at 6 weeks and recorded all complications, infections and reoperations. The three groups were than compared for statistical analysis

Detailed description

Background: Wound healing remains a concern in primary total joint arthroplasty given the risk of deep infections arising from hematomas, wound separations, and superficial infections. If wound additives can prevent these early complications, their universal application would be cost effective. This study examined whether two wound additives, Platelet-Rich Plasma (PRP) and CellerateRX® (activated collagen), would improve postoperative wound healing and reduce complications in primary total joint arthroplasty. Methods: A prospective, randomized, controlled study using three cohorts with 30 patients each (Group 1: PRP, Group 2: activated collagen, Group 3: control) were examined postoperatively at two and six weeks, at which time the following data were recorded: six wound measurements, total postoperative blood loss, complications of superficial infections, and reoperations.

Interventions

BIOLOGICALPlatelet Rich Plasma
BIOLOGICALCellerate

Sponsors

Salt Lake Orthopedic Clinic
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Masking description

computer generated randomization

Intervention model description

3 groups with identical surgical closures randomized into 2 groups with wound additives and the third group without wound additives.

Eligibility

Sex/Gender
ALL
Age
50 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

* Osteoathritis of knee and hip

Exclusion criteria

* Inflammatory arthritis and hypercoagulable state

Design outcomes

Primary

MeasureTime frameDescription
Wound Status6 weeks post operativewound hematoma, dehiscence, superficial infection

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026